FDA approves olanzapine monthly subQ LAI (Weltruza)

The FDA approved Weltruza, a once-monthly subcutaneous olanzapine long-acting injectable, on 2026-10-09 for psychotic disorders. It was developed by Teva with Medincell's SteadyTeq technology and supported by the SOLARIS trial (NCT05693935). Unlike olanzapine's existing LAI, it requires no loading dose, oral overlap or post-injection monitoring; psychiatrists discussing it flagged cost and insurance coverage as open questions.